Guardant Health, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
A Delaware federal judge rejected Tempus AI's bid to dismiss Guardant Health's lawsuit alleging patent infringement. The case involves technology for analyzing cancer-related genetic data. Guardant Health claims Tempus AI violated its patents.
TwinStrand Biosciences and the University of Washington won a patent infringement case against Guardant Health, with the court awarding $245.2M in damages and royalties. The judgement upholds a jury verdict that Guardant willfully infringed two patents and must pay a 6% royalty on relevant sales until 2033. The court also affirmed the validity of the patents in question.
Guardant Health was ordered to pay $245.2m to TwinStrand Biosciences and the University of Washington for patent infringement. The ruling covers 11 products, including Guardant360 CDx, and includes damages, royalties, and interest. Guardant plans to appeal, while TwinStrand affirms its commitment to its intellectual property.
Over the past 7 days, alphai's AI scored 4 news stories mentioning GH (Guardant Health, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 4 bearish.
Recent GH coverage spans financial news, regulation and insider activity.
In the last 30 days, GH insiders filed 17 SEC Form 4 transactions — no purchases and 17 sales ($27.3M). The most active reporter was Monroe Terilyn J., Chief People Officer, with 5 filings. 6% of those filings were made under pre-arranged Rule 10b5-1 plans.
The lawsuit continuation may increase legal expenses and uncertainty for Guardant Health.
Potential downward pressure on Guardant Health stock due to large liability and future royalty obligations.
Significant liability may pressure Guardant's stock and cash flow.
The insider sale may signal short-term downside pressure but size is modest relative to market cap.
Significant legal liability and ongoing royalty obligations will pressure earnings and cash flow.
alphai scores every news story that mentions GH with an AI model for sentiment and relevance, and aggregates insider trades from Guardant Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
A Delaware federal judge rejected Tempus AI's bid to dismiss Guardant Health's lawsuit alleging patent infringement. The case involves technology for analyzing cancer-related genetic data. Guardant Health claims Tempus AI violated its patents.
1 min readTwinStrand Biosciences and the University of Washington won a patent infringement case against Guardant Health, with the court awarding $245.2M in damages and royalties. The judgement upholds a jury verdict that Guardant willfully infringed two patents and must pay a 6% royalty on relevant sales until 2033. The court also affirmed the validity of the patents in question.
2 min readGuardant Health was ordered to pay $245.2m to TwinStrand Biosciences and the University of Washington for patent infringement. The ruling covers 11 products, including Guardant360 CDx, and includes damages, royalties, and interest. Guardant plans to appeal, while TwinStrand affirms its commitment to its intellectual property.
2 min readTalasaz AmirAli (Co-Chief Executive Officer) sold 37,500 indirectly-held shares of Guardant Health, Inc. (GH) at an average of $169.16 ($168.20–$170.29, $6.34M total) across 3 trades on 2026-08-21.
1 min readGuardant Health (GH) lost a patent dispute and was ordered to pay $245.2M in damages, royalties, and interest. The company must also pay a 6% royalty on sales of key products, including Guardant360 and Shield tests. The ruling caused GH stock to decline.
1 min readGuardant Health (GH) shares rose 4.3% following strong Q2 results, with revenue up 44% YoY to $335M. The company raised its 2026 revenue guidance to $1.34B-$1.36B, citing rapid adoption of its Shield colorectal cancer test. Analysts increased price targets post-earnings, and UnitedHealth Group added Shield to its coverage.
3 min readAristotle Capital Management’s Core Equity Fund Q2 2026 letter said its fund gained 14.69% in Q2 2026. It highlighted Guardant Health (GH), citing FDA approval of an updated Guardant360 liquid biopsy test, American Cancer Society inclusion of its Shield colorectal screening test, and stronger-than-expected Q1 earnings. GH closed Aug. 14, 2026 near $157.21.
6 min readGuardant Health (GH) director Ian T. Clark sold 14,180 shares on Aug. 4, 2026, via an exercise-and-sell of options with a $50.57 strike, according to an SEC Form 4. The weighted average sale price was $158.92, totaling about $2.3 million. Clark reported no direct shares after the sale; the company had about $21.4B market cap and $159.79 closing price.
4 min readMonroe Terilyn J. (Chief People Officer) sold 46,300 shares of Guardant Health, Inc. (GH) at an average of $165.12 ($163.41–$167.92, $7.65M total) across 5 trades on 2026-08-12.
1 min readGuardant Health (NASDAQ:GH) director Ian T. Clark sold 14,180 shares indirectly on Aug. 4, 2026 via an exercise-and-sell of options with a $50.57 strike, for about $2.3 million, at a weighted average price of $158.92. After the sale, indirect holdings fell to 2,975 shares. Guardant reported TTM revenue of $1.2 billion and a net loss of $453.4 million.
3 min read
